Insomnia and Anxiety Form a Vicious Cycle With Shared Brain Mechanisms
New review reveals insomnia and generalized anxiety disorder reinforce each other through overlapping neurobiology—and treating sleep may break the cycle.
Summary
A 2025 review in Sleep Medicine examines the bidirectional relationship between generalized anxiety disorder (GAD) and insomnia. Affecting 3–6% of the global population, GAD frequently co-occurs with severe sleep disturbances. The review finds that anxiety drives physiological and cognitive arousal that disrupts sleep, while insomnia worsens emotional dysregulation and amplifies worry—sometimes preceding anxiety onset. Shared neurobiological mechanisms include hyperactive HPA axis stress responses, elevated amygdala reactivity, weakened prefrontal control, and GABAergic deficits. Importantly, cognitive behavioral therapy for insomnia (CBT-I) improved both sleep and anxiety symptoms even without directly targeting anxiety, suggesting sleep-focused treatment may be a powerful entry point for managing GAD.
Detailed Summary
Generalized anxiety disorder affects millions worldwide and is notorious for its persistence and overlap with other psychiatric conditions. One of its most debilitating—yet sometimes overlooked—features is chronic sleep disruption, particularly insomnia. This 2025 review synthesizes clinical and neurobiological evidence to clarify exactly how tightly insomnia and GAD are intertwined.
The authors argue that the relationship is genuinely bidirectional. Anxiety fuels hyperarousal—both cognitive (racing thoughts, worry) and physiological (elevated cortisol, heightened heart rate)—that makes falling and staying asleep extremely difficult. But the reverse is equally true: sleep deprivation impairs emotional regulation, lowers stress tolerance, and amplifies the very worry patterns that define GAD. Longitudinal data even suggest insomnia can precede and predict the development of anxiety disorders, not merely follow them.
At the neurobiological level, the two conditions share striking commonalities. Both involve dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, heightened amygdala reactivity to threat cues, reduced inhibitory control from the prefrontal cortex, and deficits in GABAergic signaling—the brain's primary calming system. This shared substrate means treating one condition may directly benefit the other.
The most actionable finding is that cognitive behavioral therapy for insomnia (CBT-I) reduced anxiety severity in GAD patients even when anxiety itself was not the direct therapeutic target. This positions CBT-I as a high-value, low-risk intervention that could be integrated earlier into GAD treatment protocols.
Caveats apply: this is a narrative review relying primarily on abstract-level synthesis, and the directionality of causation in individual patients remains difficult to establish. Most studies reviewed focus on clinical populations, limiting generalizability to subclinical anxiety. Nonetheless, the clinical implications are clear and actionable.
Key Findings
- Insomnia and GAD share a bidirectional relationship—each worsens the other independently.
- Both conditions involve HPA axis hyperactivity, elevated amygdala reactivity, and GABAergic deficits.
- Insomnia can precede and predict anxiety disorder onset, not just accompany it.
- CBT-I improved anxiety severity in GAD patients even without directly targeting anxiety.
- GAD affects 3–6% of the global population, with insomnia among its most disabling symptoms.
Methodology
This is a narrative review synthesizing clinical and neurobiological research on the overlap between GAD and insomnia. The authors draw on neuroimaging, psychophysiological, and treatment outcome studies. No original data were collected; conclusions are based on existing literature synthesis.
Study Limitations
As a narrative review, the paper is susceptible to selection bias and cannot establish causality between insomnia and GAD. The authors had access only to an abstract for this summary, limiting depth of methodological critique. Most underlying studies involve clinical GAD populations, reducing applicability to subclinical or community samples.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: